Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA1 | P56199 | 4/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 4/20 | 0.46 |
| ▸ | PGR | P06401 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2157624 | 0.88 | CNR1 (0.49) | ITGA1CNR1MEN1KMT2APOLB | |
| SCHEMBL2157528 | 0.86 | PFKFB3 (0.52) | ITGA1CNR1MEN1KMT2AMAPT | |
| SCHEMBL2158501 | 0.81 | CNR1 (0.49) | CNR1MEN1KMT2ALMNAMAPT | |
| SCHEMBL7577795 | 0.80 | ITGA1 (0.74) | ITGA1MEN1KMT2ALMNAMAPT | |
| SCHEMBL2158080 | 0.80 | CNR1 (0.42) | CNR1MEN1KMT2AACLY | |
| SCHEMBL2162763 | 0.80 | CDK1 (0.54) | CNR1MEN1KMT2APOLBPGR | |
| SCHEMBL2157826 | 0.79 | KDM1A (0.48) | CNR1MEN1KMT2AMAPTPGR | |
| SCHEMBL2157979 | 0.79 | KDM1A (0.59) | CNR1KDM1AMAOA | |
| SCHEMBL2158458 | 0.78 | PGR (0.55) | CNR1MEN1KMT2ALMNAMAPT | |
| SCHEMBL2158492 | 0.77 | USP2 (0.49) | LMNAMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985769-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2006-06-29 | — | — | US | disclosed |
| US-6881741-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | HAVCR2, ZC3HAV1, MAVS | ITGA1 3767/4885CNR1 3333/4885MEN1 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.